Core Insights - Boston Scientific's Endoscopy business is a vital part of its MedSurg segment, focusing on innovative, less invasive technologies for gastrointestinal and pulmonary conditions, with net sales of $2.16 billion in the first nine months of 2025, accounting for 15% of total sales [2][9] - The endoscopy market is valued at $8 billion and is projected to grow at approximately 6% from 2026 to 2028, with Boston Scientific aiming to exceed this growth while improving operating margins [2][9] Business Segments - The Endoscopy portfolio is divided into four key areas, including pancreaticobiliary, which features products like SpyGlass and EXALT D, with plans to launch a capital platform next year to enhance imaging technologies using AI [3] - Endoluminal surgery is another significant area, with innovations such as MANTIS and OverStitch, facilitating the transition from traditional operating rooms to endoscopic therapies through improved tools [4] - The company is also focusing on Endobariatrics, offering minimally invasive weight loss solutions through the Endura Weight Loss Solutions, targeting the obesity market [5] Market Performance - Boston Scientific's shares have increased by 5.5% over the past year, outperforming the industry average increase of 0.1% [8] - The stock is currently trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.90, which is above both its median and the industry average [10] Earnings Estimates - Earnings estimates for Boston Scientific are trending upward, with the current quarter estimate at $0.78 and the next year estimate at $3.45 [11][12]